The future is predetermined in severe sepsis, so what are the implications?

Critical Care Medicine

Volumn 38, Issue 10 SUPPL., 2010, Pages

  Lukaszewicz, Anne Claire ^a   Payen, Didier ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Biomarker; Genetic; Genomewide; Genomic; Inflammation; Outcome; Predetermination; Predisposition; Prognosis; Septic shock; Transcriptome

Indexed keywords

ACTIVATED PROTEIN C; CALGRANULIN; CALGRANULIN A; HIGH MOBILITY GROUP B1 PROTEIN; HYDROCORTISONE; INTERLEUKIN 10; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; PROTEIN S 100; TOLL LIKE RECEPTOR 4;

CONFERENCE PAPER; DIABETES MELLITUS; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE ORGAN FAILURE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; RESUSCITATION; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78650312844     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181f23dc4     Document Type: Conference Paper

References (62)

1. Fisher CJ Jr, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein: The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334:1697-1702
2. Fisher CJ Jr, Dhainaut JF, Opal SM, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial: Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994;271:1836-1843
3. Minneci PC, Deans KJ, Banks SM, et al: Meta-analysis: The effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004;141:47-56
4. Remick DG: Cytokine therapeutics for the treatment of sepsis: Why has nothing worked? Curr Pharm Des 2003;9:75-82
5. Pachot A, Lepape A, Vey S, et al: Systemic transcriptional analysis in survivor and non-survivor septic shock patients: A preliminary study. Immunol Lett 2006;106:63-71
6. Wong HR, Shanley TP, Sakthivel B, et al: Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. Physiol Genomics 2007;30:146-155
7. Calvano SE, Xiao W, Richards DR, et al: A network-based analysis of systemic inflammation in humans. Nature 2005;437:1032-1037
8. Alberti C, Brun-Buisson C, Burchardi H, et al: Epidemiology of sepsis and infection in ICU patients from an international multicen-tre cohort study. Intensive Care Med 2002;28:108-121
9. Yende S, D'Angelo G, Kellum JA, et al: Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008;177:1242-1247
10. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
11. Dehoux MS, Boutten A, Ostinelli J, et al: Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994;150:710-716
12. Cavaillon JM, Annane D: Compartmentaliza-tion of the inflammatory response in sepsis and SIRS. J Endotoxin Res 2006;12:151-170
13. Annane D, Sebille V, Charpentier C, et al: Effect of treatment with low doses of hydro-cortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-871
14. Rivers E, Nguyen B, Havstad S, et al: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-1377
15. Sprung CL, Annane D, Keh D, et al: Hydro-cortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-124
16. Singer M, De Santis V, Vitale D, et al: Multi-organ failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet 2004;364:545-548
17. Mira JP, Cariou A, Grall F, et al: Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 1999;282:561-568
18. Stuber F, Petersen M, Bokelmann F, et al: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996;24:381-384
19. Villar J, Maca-Meyer N, Perez-Mendez L, et al: Bench-to-bedside review: Understanding genetic predisposition to sepsis. Crit Care 2004;8:180-189
20. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 2006;124:783-801
21. Arbour NC, Lorenz E, Schutte BC, et al: TLR4 mutations are associated with endo-toxin hyporesponsiveness in humans Nat Genet 2000;25:187-191
22. Lorenz E, Mira JP, Frees KL, et al: Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002;162:1028-1032
23. Smirnova I, Mann N, Dols A, et al: Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningo-coccal susceptibility. Proc Natl Acad Sci U S A 2003;100:6075-6080
24. Marchini J, Howie B, Myers S, et al: A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 2007;39:906-913
25. Chasman DI, Pare G, Mora S, et al: Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet 2009;5: e1000730
26. Boldrick JC, Alizadeh AA, Diehn M, et al: Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci U S A 2002;99:972-977
27. Huang Q, Liu D, Majewski P, et al: The plasticity of dendritic cell responses to pathogens and their components. Science 2001;294:870-875
28. Talwar S, Munson PJ, Barb J, et al: Gene expression profiles of peripheral blood leukocytes after endotoxin challenge in humans. Physiol Genomics 2006;25:203-215
29. Cvijanovich N, Shanley TP, Lin R, et al: Validating the genomic signature of pediatric septic shock. Physiol Genomics 2008;34:127-134
30. Payen D, Lukaszewicz AC, Belikova I, et al: Gene profiling in human blood leucocytes during recovery from septic shock. Intensive Care Med 2008;34:1371-1376
31. Prucha M, Ruryk A, Boriss H, et al: Expression profiling: toward an application in sepsis diagnostics. Shock 2004;22:29-33
32. Tang BM, McLean AS, Dawes IW, et al: Gene-expression profiling of peripheral blood mononuclear cells in sepsis. Crit Care Med 2009;37:882-888
33. Rangel-Frausto MS, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995;273:117-123
34. Abraham E, Laterre PF, Garbino J, et al: Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1, 342 patients. Crit Care Med 2001;29:503-510
35. Lima A, van Bommel J, Jansen TC, et al: Low tissue oxygen saturation at the end of early goal-directed therapy is associated with worse outcome in critically ill patients. Crit Care 2009;13(Suppl 5): S13
36. Levy B, Dusang B, Annane D, et al: Cardiovascular response to dopamine and early prediction of outcome in septic shock: A prospective multiple-center study. Crit Care Med 2005;33:2172-2177
37. Annane D, Bellissant E, Sebille V, et al: Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 1998;46:589-597
38. Bollaert PE, Charpentier C, Levy B, et al: Reversal of late septic shock with supraphysi-ologic doses of hydrocortisone. Crit Care Med 1998;26:645-650
39. Briegel J, Forst H, Haller M, et al: Stress doses of hydrocortisone reverse hyperdy-namic septic shock: A prospective, randomized, double-blind, single-center study. Crit Care Med 1999;27:723-732
40. Belikova I, Lukaszewicz AC, Faivre V, et al: Oxygen consumption of human peripheral blood mononuclear cells in severe human sepsis. Crit Care Med 2007;35:2702-2708
41. Fink MP: Cytopathic hypoxia: Mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. Crit Care Clin 2001;17:219-237
42. Hotchkiss RS, Swanson PE, Freeman BD, et al: Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999;27:1230-1251
43. Hynninen M, Pettila V, Takkunen O, et al: Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and-10 levels in critically ill patients with sepsis. Shock 2003;20:1-4
44. Lekkou A, Karakantza M, Mouzaki A, et al: Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. Clin Diagn Lab Immunol 2004;11:161-167
45. Payen D, Faivre V, Lukaszewicz AC, et al: Expression of monocyte human leukocyte antigen-DR in relation with sepsis severity and plasma mediators. Minerva Anestesiol 2009;75:484-493
46. Lukaszewicz AC, Grienay M, Resche-Rigon M, et al: Monocytic HLA-DR expression in intensive care patients: Interest for prognosis and secondary infection prediction. Crit Care Med 2009;37:2746-2752
47. Monneret G, Lepape A, Voirin N, et al: Persisting low monocyte human leukocyte anti-gen-DR expression predicts mortality in septic shock. Intensive Care Med 2006;32:1175-1183
48. Rothwell PM, Lawler PG: Prediction of outcome in intensive care patients using endocrine parameters. Crit Care Med 1995;23:78-83
49. Smeeth L, Thomas SL, Hall AJ, et al: Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004;351:2611-2618
50. Sunden-Cullberg J, Norrby-Teglund A, Rou-hiainen A, et al: Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005;33:564-573
51. Adib-Conquy M, Cavaillon JM: Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS Lett 2007;581:3723-3733
52. Kono H, Rock KL: How dying cells alert the immune system to danger. Nat Rev Immunol 2008l 8:279-289
53. Wang H, Bloom O, Zhang M, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1992;85:248-251
54. Lim SY, Raftery MJ, Goyette J, et al: Oxida-tive modifications of S100 proteins: Functional regulation by redox. J Leukoc Biol 2009;86:577-587
55. Angus DC, Yang L, Kong L, et al: Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med 2007;35:1061-1067
56. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008;34:17-60
57. Payen D, Mateo J, Cavaillon JM, et al: Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: A randomized controlled trial. Crit Care Med 2009;37:803-810
58. Hackam DG, Mamdani M, Li P, et al: Statins and sepsis in patients with cardiovascular disease: A population-based cohort analysis. Lancet 2006;367:413-418
59. Luyt CE, Combes A, Deback C, et al: Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 2007;175:935-942
60. Vincent A, La Scola B, Forel JM, et al: Clinical significance of a positive serology for mimivirus in patients presenting a suspicion of ventilator-associated pneumonia. Crit Care Med 2009;37:111-118
61. McCullers JA: Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006;19:571-582
62. Dawood FS, Jain S, Finelli L, et al: Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360:2605-2615